MindMed MNMD announced its financial results for the first quarter of 2022, which ended March 31.
Financial highlights
As of March 31, 2022, MindMed’s cash balance totaled $120.5 million, compared to $133.5 million as of December 31 of last year.
The net cash used in operating activities was $12.9 million for the first three months of the year, compared to $10.0 million for Q1 of 2021.
Research and development expenses were $10.2 million, compared to $6.8 million for the same period in 2021. The increase of $3.4 million was primarily due to $4.4 million of internal expenses related to compensation costs for an additional headcount of $2.0 million and an increase in non-cash expenses of $1.7 million of stock-based compensation expenses. This increase was counterbalanced by a decrease in external spending of $0.8 million related to preclinical and other programs.
General and administrative expenses were $8.3 million, compared to $7.0 million for the same period in 2021. The increase of $1.2 million was predominantly due to an increase of $0.9 million in non-cash stock-based compensation expenses.
The net and comprehensive loss was $18.5 million, compared to $13.8 million for the same period in 2021.
Company highlights
It is expected that a Phase 2a trial of MM-120, a pharmaceutically optimized form of LSD, in chronic pain conditions to initiate in Q4 2022.
In December 2021, the company completed MMED003, a Phase 1 trial of MM-110, a congener of ibogaine. The successful results of this Phase 1 study have informed the Phase 2a trial design that is expected to be initiated in Q2 2022.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!